


Designed to help you achieve haemostasis

## Veriset™ Hemostatic Patch

- Fast and effective<sup>1</sup>
- Increased patient safety<sup>2</sup>
- Ease of use<sup>1,2</sup>
- Potential cost saving<sup>4,5</sup>

¥ Effective despite coagulation/clotting deficiency (based on serum plasma morphology)



## Potential Cost Savings

Potentially lowering the costs associated with surgery and postoperative patient management<sup>4,5</sup>

"Bleeding is detrimental and costly. Prevention of bleeding and transfusion can be expected to have tremendous effects on reallocation of resources"<sup>4</sup>

"Peri-operative blood loss during liver surgeries may add significant burden to hospital resources and costs"<sup>5</sup>

"Patients with peri-operative blood loss possibly tend to stay significantly longer in the hospital and may have a higher mortality rate compared to those who do not experience peri-operative blood loss"<sup>5</sup>

CFN	Description - Veriset Medtronic	Pack Size
HP0204E	Veriset™ 2cm x 4cm hemostatic patch	6
HP0505E	Veriset™ 5cm x 5cm hemostatic patch	6
HP0510E	Veriset™ 5cm x 10cm hemostatic patch	6
HP0204E1	Veriset™ 2cm x 4cm hemostatic patch	1
HP0505E1	Veriset™ 5cm x 5cm hemostatic patch	1
HP0510E1	Veriset™ 5cm x 10cm hemostatic patch	1
HP0816E1	Veriset™ 8cm x 16cm hemostatic patch	1
HP0204CVE	Veriset™ 2cm x 4cm CV Template	6



### References:

1. Öllinger, R, et al, A multicenter, randomized clinical trial comparing the Veriset™ haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery, HPB (Oxford), 2012 Dec 27, doi: 10.1111/hpb.12009 [epub ahead of print].
2. Veriset™ haemostatic patch Instructions For Use and Product Specifications (2014).
3. Preclinical study sponsored by Covidien in 2010 assessing CV and PV models on animals with inhibited platelet activity (heparin, aspirin, Plavix™).
4. Shander, A, MD, Financial and clinical outcomes associated with surgical bleeding complications, Surgery 2007; 142: S20-S25.
5. Parikh, N, Hashemi, L, Morseon, M, Ally, A, Resource utilization and costs associated with peri-operative blood loss during liver surgeries - A retrospective data analysis in the United States, Covidien USA & Covidien UK, IHPBA 2012.
6. Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger HJ, Gassel HJ, Rokkjaer M, Schauer R, Larsen PN, Tetens V, Büchler MW. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011 Jan;149(1):48-55.
7. Oz MC, Cosgrove DM 3rd, Badduke BR, Hill JD, Flannery MR, Palumbo R, Topic N. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg. 2000 May;69(5):1376-82.
8. Genyk Y, Kato T, Pomposelli JJ, Wright JK Jr, Sher LS, Tetens V, Chapman WC. Fibrin Sealant Patch (TachoSil) vs Oxidized Regenerated Cellulose Patch (Surgical Original) for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection: A Randomized Controlled Trial. J Am Coll Surg. 2016 Mar;222(3):261-8. doi: 10.1016/j.jamcollsurg.2015.12.007. Epub 2015 Dec 18. PMID: 26776356.
9. S.P. Saha et al A prospective randomized study comparing fibrin sealant to manual compression for the treatment of anastomotic suture-hole bleeding in expanded polytetrafluoroethylene grafts J. Vasc. Surg., 56 (2012), pp. 134-141- for Tisseel

India Medtronic Pvt Ltd  
1261, Solitaire Corporate Park Building No. 12, 6th Floor  
Andheri-Ghatkopar Link Road, Andheri (E), Mumbai - 400 093  
For more information, please contact: 080 48971329  
Email: rs.indiainsidesales@medtronic.com

[medtronic.co.in/veriset](http://medtronic.co.in/veriset)

©2022 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.




## Medtronic

## Veriset™ Hemostatic Patch

Fast, effective,  
and simple to use.<sup>1,2</sup>


Designed to perform when you need it the most.




Medtronic

## Increased Patient Safety<sup>2</sup>

Unlike any other high-efficacy haemostat, Veriset™ haemostatic patch is 100% free of human or animal components<sup>2</sup>, eliminating the risk of viral transmission.




## Universal use<sup>2</sup> - effective in cases of inhibited coagulation and independent of clotting ability<sup>3</sup>




## Clinical Performance<sup>1</sup>

Fast and effective, allowing haemostasis in ~1 min<sup>†,1</sup>



GRAPH 1: Median time for 75% of patients to achieve haemostasis with Veriset and competitive products.

## 66% faster than its nearest competitor brand's surgical patch<sup>1</sup>



<sup>†</sup> Compared to other available haemostatic products studied in different anatomical locations.  
<sup>1</sup> According to competitor brand's<sup>2</sup> prescribing information

CHART 1: Percentage of patients reaching haemostasis in a multicentre randomised clinical trial for bleeding management in hepatic surgery (50 out of 101 randomised patients: Veriset™ haemostatic patch n=32, competitor brand's patch n=18).

## Ease of Use<sup>2</sup>

No special storage requirements  
 guarantee easy access when needed<sup>2</sup>

Refer to IFU for full details.

Ready to use in both open and laparoscopic procedures with no preparation time<sup>2</sup>

Please refer to the Instructions For Use for complete indications and application instructions

### Instructions for use in open procedures

- Open the foil pouch ensuring you use the Veriset patch within 60 minutes after opening. The patch should not be hydrated prior to placement.
- Place the darker side of Veriset haemostatic patch on the bleeding site, extending ~1-2 cm beyond the bleeding site (the patch may be cut as necessary for the desired application).
- Hold firmly in place to ensure proper adherence to the bleeding site. After 30 seconds, discontinue pressure and inspect the bleeding site.
- If bleeding has not stopped, reapply pressure and reassess after 30 seconds. If haemostasis is not obtained, additional patch(es) may be applied over the existing material or as replacement for the initial material applied.
- Non-hydrated portions of Veriset haemostatic patch can be removed by cutting along the edges or be adhered to the surface by hydrating with saline and applying pressure.
- Do not remove Veriset haemostatic patch at the end of surgery. The implant will absorb after approximately 28 days.

